Tower Research Capital (TRC)’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-887
| Closed | -$86K | – | 4852 |
|
|
2019
Q3 | $86K | Buy |
887
+868
| +4,568% | +$86.9K | 0.01% | 1447 |
|
|
2019
Q2 | $2K | Sell |
19
-414
| -96% | -$44.7K | ﹤0.01% | 3378 |
|
|
2019
Q1 | $49K | Buy |
+433
| New | +$31.8K | ﹤0.01% | 1779 |
|
|
2018
Q4 | – | Sell |
-4,085
| Closed | -$223K | – | 4664 |
|
|
2018
Q3 | $223K | Buy |
4,085
+4,074
| +37,036% | +$279K | 0.02% | 923 |
|
|
2018
Q2 | $1K | Sell |
11
-1,634
| -99% | -$126K | ﹤0.01% | 3561 |
|
|
2018
Q1 | $110K | Buy |
+1,645
| New | +$95K | 0.01% | 1198 |
|
|
2017
Q4 | – | Sell |
-2,962
| Closed | -$264K | – | 4311 |
|
|
2017
Q3 | $264K | Buy |
+2,962
| New | +$225K | 0.02% | 557 |
|
|
2017
Q2 | – | Sell |
-300
| Closed | -$16K | – | 3818 |
|
|
2017
Q1 | $16K | Sell |
300
-2,371
| -89% | -$141K | ﹤0.01% | 1461 |
|
|
2016
Q4 | $133K | Buy |
2,671
+2,325
| +672% | +$125K | 0.01% | 832 |
|
|
2016
Q3 | $21K | Buy |
+346
| New | +$19.9K | ﹤0.01% | 1602 |
|
|
2016
Q2 | – | Sell |
-4,819
| Closed | -$206K | – | 5286 |
|
|
2016
Q1 | $142K | Buy |
4,819
+4,325
| +876% | +$136K | 0.02% | 408 |
|
|
2015
Q4 | $22K | Buy |
+494
| New | +$25.9K | ﹤0.01% | 1224 |
|
|
2015
Q2 | – | Sell |
-480
| Closed | -$37K | – | 5325 |
|
|
2015
Q1 | $37K | Buy |
+480
| New | +$27.6K | ﹤0.01% | 1737 |
|
Tower Research Capital (TRC)'s ONCE Position: Q4 2019 in Review
Tower Research Capital (TRC) sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 887 shares — an estimated $86K sold.
Tower Research Capital (TRC) first reported a position in ONCE in Q1 2015 and held it in 13 quarters. The position peaked at $264K in Q3 2017. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Tower Research Capital (TRC) reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Tower Research Capital (TRC) sold 887 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $86K.
- Tower Research Capital (TRC) first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 13 quarters.
- Tower Research Capital (TRC)'s Spark Therapeutics, Inc. Common Stock position peaked at $264K in Q3 2017.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2019, filed 7 Feb 2020.